Skip to main content
Figure 5 | Arthritis Research & Therapy

Figure 5

From: Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Figure 5

Antiadalimumab antidrug antibodies can be masked by the presence of adalimumab in serum. Trough serum adalimumab levels (A) and antiadalimumab antidrug antibody (ADAb) titres (B) at the end of treatment (2 weeks after the last injection) and at follow-up (upon relapse or, in absence of relapse, at 16 weeks after discontinuation). *P < 0.05 assessed by Wilcoxon signed-rank test.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us